Janux Therapeutics Inc (JANX)
61.47
-0.72
(-1.16%)
USD |
NASDAQ |
May 07, 15:58
Janux Therapeutics Cash from Operations (TTM): -50.58M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -50.58M |
| September 30, 2023 | -52.59M |
| June 30, 2023 | -54.29M |
| March 31, 2023 | -45.31M |
| December 31, 2022 | -42.92M |
| September 30, 2022 | -41.49M |
| June 30, 2022 | -33.93M |
| Date | Value |
|---|---|
| March 31, 2022 | -34.06M |
| December 31, 2021 | -16.98M |
| September 30, 2021 | -8.124M |
| June 30, 2021 | -3.353M |
| March 31, 2021 | 2.07M |
| December 31, 2020 | -4.369M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-54.29M
Minimum
Jun 2023
2.07M
Maximum
Mar 2021
-29.69M
Average
-34.06M
Median
Mar 2022
Cash from Operations (TTM) Benchmarks
| Viking Therapeutics Inc | -54.87M |
| Equillium Inc | -21.78M |
| Minerva Neurosciences Inc | -20.76M |
| Arvinas Inc | -347.80M |
| Calidi Biotherapeutics Inc | -- |